{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:59:37Z","timestamp":1791921577373,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173076"],"award-info":[{"award-number":["82173076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103485"],"award-info":[{"award-number":["82103485"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["20Y11904900"],"award-info":[{"award-number":["20Y11904900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022YQ014"],"award-info":[{"award-number":["2022YQ014"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2022CRD034"],"award-info":[{"award-number":["SHDC2022CRD034"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020732","name":"Innovative Research Team of High-level Local Universities in Shanghai.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-01977-z","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T14:02:42Z","timestamp":1678284162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer"],"prefix":"10.1007","volume":"40","author":[{"given":"Di","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-8141","authenticated-orcid":false,"given":"Haige","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"1","key":"1977_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"1977_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324(19):1980\u201391. https:\/\/doi.org\/10.1001\/jama.2020.17598.","journal-title":"JAMA"},{"issue":"5","key":"1977_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma in situ)\u20142019 update. Eur Urol. 2019;76(5):639\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016.","journal-title":"Eur Urol"},{"issue":"1","key":"1977_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"issue":"16","key":"1977_CR5","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"International Collaboration of Trialists","year":"2011","unstructured":"International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.32.3139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1977_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/JU.0000000000000593","volume":"203","author":"CR Ritch","year":"2020","unstructured":"Ritch CR, Velasquez MC, Kwon D, et al. Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol. 2020;203(3):505\u201311. https:\/\/doi.org\/10.1097\/JU.0000000000000593.","journal-title":"J Urol"},{"issue":"1","key":"1977_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","volume":"48","author":"J Huguet","year":"2005","unstructured":"Huguet J, Crego M, Sabat\u00e9 S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol. 2005;48(1):53\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2005.03.021.","journal-title":"Eur Urol"},{"issue":"3","key":"1977_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19(3):666\u201375. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.666.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1977_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","volume":"22","author":"FJ Bianco Jr","year":"2004","unstructured":"Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol. 2004;22(4):290\u20134. https:\/\/doi.org\/10.1016\/S1078-1439(03)00144-3.","journal-title":"Urol Oncol"},{"issue":"11","key":"1977_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"issue":"7","key":"1977_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1977_CR12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706\u201314. https:\/\/doi.org\/10.1038\/s41591-019-0628-7.","journal-title":"Nat Med"},{"issue":"34","key":"1977_CR13","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(34):3353\u201360. https:\/\/doi.org\/10.1200\/JCO.18.01148.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1977_CR14","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"issue":"3","key":"1977_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014.","journal-title":"Immunity"},{"key":"1977_CR16","doi-asserted-by":"publisher","first-page":"3820956","DOI":"10.1155\/2018\/3820956","volume":"2018","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Xie R, Lin S, You X, Weng X. Anti-PD-1\/PD-L1 antibody therapy for pretreated advanced or metastatic nonsmall cell lung carcinomas and the correlation between PD-L1 expression and treatment effectiveness: an update meta-analysis of randomized clinical trials. Biomed Res Int. 2018;2018:3820956. https:\/\/doi.org\/10.1155\/2018\/3820956.","journal-title":"Biomed Res Int"},{"issue":"1","key":"1977_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.juro.2012.02.2558","volume":"188","author":"AC Small","year":"2012","unstructured":"Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012;188(1):21\u20136. https:\/\/doi.org\/10.1016\/j.juro.2012.02.2558.","journal-title":"J Urol"},{"issue":"1","key":"1977_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.31165","volume":"73","author":"JC Ahn","year":"2021","unstructured":"Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422\u201336. https:\/\/doi.org\/10.1002\/hep.31165.","journal-title":"Hepatology"},{"issue":"7","key":"1977_CR19","doi-asserted-by":"publisher","first-page":"e0254433","DOI":"10.1371\/journal.pone.0254433","volume":"16","author":"H Jiang","year":"2021","unstructured":"Jiang H, Gu X, Zuo Z, Tian G, Liu J. Prognostic value of circulating tumor cells in patients with bladder cancer: a meta-analysis. PLoS ONE. 2021;16(7):e0254433. https:\/\/doi.org\/10.1371\/journal.pone.0254433.","journal-title":"PLoS ONE"},{"issue":"6","key":"1977_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.7150\/thno.5195","volume":"3","author":"B Hong","year":"2013","unstructured":"Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics. 2013;3(6):377\u201394. https:\/\/doi.org\/10.7150\/thno.5195.","journal-title":"Theranostics."},{"issue":"9","key":"1977_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41551-018-0257-3","volume":"2","author":"O Vermesh","year":"2018","unstructured":"Vermesh O, Aalipour A, Ge TJ, et al. An intravascular magnetic wire for the high-throughput retrieval of circulating tumour cells in vivo. Nat Biomed Eng. 2018;2(9):696\u2013705. https:\/\/doi.org\/10.1038\/s41551-018-0257-3.","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"1977_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/cancers11060802","volume":"11","author":"J Budna-Tukan","year":"2019","unstructured":"Budna-Tukan J, \u015awierczewska M, Mazel M, et al. Analysis of circulating tumor cells in patients with non-metastatic high-risk prostate cancer before and after radiotherapy using three different enumeration assays. Cancers (Basel). 2019;11(6):802. https:\/\/doi.org\/10.3390\/cancers11060802.","journal-title":"Cancers (Basel)."},{"issue":"7492","key":"1977_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322. https:\/\/doi.org\/10.1038\/nature12965.","journal-title":"Nature"},{"issue":"3","key":"1977_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-556.e25. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007.","journal-title":"Cell"},{"issue":"4","key":"1977_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006.","journal-title":"Eur Urol"},{"issue":"7","key":"1977_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrurol.2014.129","volume":"11","author":"W Choi","year":"2014","unstructured":"Choi W, Czerniak B, Ochoa A, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(7):400\u201310. https:\/\/doi.org\/10.1038\/nrurol.2014.129.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"1977_CR27","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/cancers11070933","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen S, Tauber G, Langsenlehner T, et al. In vivo detection of circulating tumor cells in high-risk non-metastatic prostate cancer patients undergoing radiotherapy. Cancers (Basel). 2019;11(7):933. https:\/\/doi.org\/10.3390\/cancers11070933.","journal-title":"Cancers (Basel)."},{"issue":"7","key":"1977_CR28","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdn786","volume":"20","author":"SJ Cohen","year":"2009","unstructured":"Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20(7):1223\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn786.","journal-title":"Ann Oncol"},{"issue":"5","key":"1977_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/his.13696","volume":"73","author":"A Hodgson","year":"2018","unstructured":"Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR. Basal-subtype bladder tumours show a \u201chot\u201d immunophenotype. Histopathology. 2018;73(5):748\u201357. https:\/\/doi.org\/10.1111\/his.13696.","journal-title":"Histopathology"},{"issue":"8","key":"1977_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781\u201391. https:\/\/doi.org\/10.1056\/NEJMoa040766.","journal-title":"N Engl J Med"},{"issue":"10","key":"1977_CR31","doi-asserted-by":"publisher","first-page":"606.e9","DOI":"10.1016\/j.urolonc.2017.05.021","volume":"35","author":"J Abrahamsson","year":"2017","unstructured":"Abrahamsson J, Aaltonen K, Engilbertsson H, et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol. 2017;35(10):606.e9-606.e16. https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.021.","journal-title":"Urol Oncol"},{"issue":"8","key":"1977_CR32","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/ijc.28830","volume":"135","author":"P Gazzaniga","year":"2014","unstructured":"Gazzaniga P, de Berardinis E, Raimondi C, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer. 2014;135(8):1978\u201382. https:\/\/doi.org\/10.1002\/ijc.28830.","journal-title":"Int J Cancer"},{"issue":"4","key":"1977_CR33","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","volume":"61","author":"M Rink","year":"2012","unstructured":"Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61(4):810\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.017.","journal-title":"Eur Urol"},{"issue":"1","key":"1977_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.urolonc.2009.10.008","volume":"30","author":"TJ Guzzo","year":"2012","unstructured":"Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ, Schoenberg MP. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol. 2012;30(1):44\u20138. https:\/\/doi.org\/10.1016\/j.urolonc.2009.10.008.","journal-title":"Urol Oncol"},{"issue":"1","key":"1977_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","volume":"16","author":"B Jordan","year":"2019","unstructured":"Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019;16(1):23\u201334. https:\/\/doi.org\/10.1038\/s41585-018-0105-y.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"1977_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrurol.2016.224","volume":"14","author":"MA Gorin","year":"2017","unstructured":"Gorin MA, Verdone JE, van der Toom E, Bivalacqua TJ, Allaf ME, Pienta KJ. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nat Rev Urol. 2017;14(2):90\u20137. https:\/\/doi.org\/10.1038\/nrurol.2016.224.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1977_CR37","doi-asserted-by":"publisher","first-page":"1738798","DOI":"10.1080\/2162402X.2020.1738798","volume":"9","author":"S Bergmann","year":"2020","unstructured":"Bergmann S, Coym A, Ott L, et al. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology. 2020;9(1):1738798. https:\/\/doi.org\/10.1080\/2162402X.2020.1738798.","journal-title":"Oncoimmunology."},{"issue":"9","key":"1977_CR38","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jtho.2021.03.028","volume":"16","author":"DM Hwang","year":"2021","unstructured":"Hwang DM, Albaqer T, Santiago RC, et al. Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer. J Thorac Oncol. 2021;16(9):1490\u2013500. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.028.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"1977_CR39","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","volume":"23","author":"BA Inman","year":"2017","unstructured":"Inman BA, Longo TA, Ramalingam S, Harrison MR. Atezolizumab: a PD-L1-blocking antibody for bladder cancer. Clin Cancer Res. 2017;23(8):1886\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1417.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1977_CR40","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","volume":"14","author":"SA Boorjian","year":"2008","unstructured":"Boorjian SA, Sheinin Y, Crispen PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14(15):4800\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0731.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1977_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.euo.2020.01.003","volume":"4","author":"IE de Kruijff","year":"2021","unstructured":"de Kruijff IE, Beije N, Martens JWM, de Wit R, Boormans JL, Sleijfer S. Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: a systematic review. Eur Urol Oncol. 2021;4(2):204\u201314. https:\/\/doi.org\/10.1016\/j.euo.2020.01.003.","journal-title":"Eur Urol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-01977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-01977-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-01977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T19:21:23Z","timestamp":1680290483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-01977-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["1977"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-01977-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"21 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The study complies with the Declaration of Helsinki and was conducted following the approval from Renji Hospital Ethics Committee. Written informed consent was obtained from all the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"113"}}